



**Australian Government**  
**Department of Health**  
 Therapeutic Goods Administration

**Public Summary**

<b>Summary for ARTG Entry:</b>	329896	Mediherb Tissue Regenex
<b>ARTG entry for</b>	Medicine Listed	
<b>Sponsor</b>	Integria Healthcare Australia Pty Ltd	
<b>Postal Address</b>	PO Box 4854, EIGHT MILE PLAINS, QLD, 4113 Australia	
<b>ARTG Start Date</b>	13/02/2020	
<b>Product Category</b>	Medicine	
<b>Status</b>	Active	
<b>Approval Area</b>	Listed Medicines	

**Conditions**

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

The Ginkgo biloba leaf extract used in the manufacture of this medicine must comply with the requirement of Identification Test B of the monograph Powdered Ginkgo Extract in the United States Pharmacopeia 32 - National Formulary 27 (USP32-NF27) as in force or existing from time to time. This condition does not apply to powdered or dried leaf.

**Products**

**1 . Mediherb Tissue Regenex**

<b>Product Type</b>	Single Medicine Product	<b>Effective Date</b>	26/02/2021
---------------------	-------------------------	-----------------------	------------

**Permitted Indications**

- Antioxidant/Reduce free radicals formed in the body
- Helps reduce/decrease free radical damage to body cells
- Maintain/support collagen formation
- Maintain/support collagen health
- Traditionally used in Western herbal medicine to alterative/blood cleanser/depurative/purifier
- Maintain/support general health and wellbeing
- Aid/assist/helps connective tissue production/formation
- Maintain/support healthy blood circulation
- Maintain/support blood circulation/flow to the peripheral areas of the body (legs, hands and feet)
- Maintain/support blood capillary health
- Maintain/support blood vessel health
- Maintain/support immune system health
- Maintain/support healthy immune system function
- Maintain/support immune system to fight illness
- Maintain/support (state vitamin/mineral/nutrient) levels in the body
- Maintain/support (state vitamin/mineral) within normal range
- Traditionally used in Western herbal medicine to decrease/reduce/relieve symptoms of mild eczema/dermatitis
- Traditionally used in Western herbal medicine to maintain/support skin health
- Maintain/support skin health
- Maintain/support wound healing
- Maintain/support skin repair/healing/regeneration
- Traditionally used in Western herbal medicine to maintain/support skin repair/healing/regeneration

**Indication Requirements**

Public Summary



**Australian Government**  
**Department of Health**  
 Therapeutic Goods Administration

Product presentation must not imply or refer to drugs/alcohol.  
 Product presentation must not imply or refer to circulatory disorders/diseases/conditions e.g. thrombosis.  
 Product presentation must only refer to detoxification in relation to natural body processes.  
 Product presentation must not imply or refer to disease in any body organ, in particular the kidney or liver.  
 Product presentation must not imply or refer to serious cardiovascular conditions.  
 Product presentation must not imply or refer to serious immunological diseases.  
 Product presentation must only refer to mild eczema.

Label statement: [Vitamins/minerals/nutrients/dietary supplements] can only be of assistance if dietary intake is inadequate OR [Vitamins/minerals/nutrients/dietary supplements] should not replace a balanced diet (or words to that effect).

Label statement: If symptoms persist, talk to your health professional.

If product is indicated for supplementation, Label statement: [Vitamins/minerals/nutrients/dietary supplements] can only be of assistance if dietary intake is inadequate OR [Vitamins/minerals/nutrients/dietary supplements] should not replace a balanced diet (or words to that effect).

**Standard Indications**

No Standard Indications included on Record

**Specific Indications**

No Specific Indications included on Record

**Warnings**

If symptoms persist, seek the advice of a healthcare professional.

WARNING: May be dangerous if taken in large amounts or for a long period. OR WARNING: Contains zinc which may be dangerous if taken in large amounts or for a long period (or words to that effect).

Vitamins and minerals can only be of assistance if dietary intake is inadequate OR Vitamin and/or mineral supplements should not replace a balanced diet.

For practitioner dispensing only.

**Additional Product information**

**Pack Size/Poison information**

<b>Pack Size</b>	<b>Poison Schedule</b>
------------------	------------------------

**Components**

**1 . Formulation 1**

<b>Dosage Form</b>	Tablet, film coated
<b>Route of Administration</b>	Oral

**Visual Identification**

**Active Ingredients**

<b>ascorbic acid</b>	<b>105 mg</b>
<b>Centella asiatica leaf Extract dry concentrate standardised</b>	<b>250 mg</b>
Equivalent: Centella asiatica (Dry)	2.5 g
<b>Ginkgo biloba leaf Dry</b>	<b>20 mg</b>
Equivalent: Ginkgo biloba (Dry)	1000 mg
<b>Vitis vinifera seed Extract dry concentrate standardised</b>	<b>30 mg</b>
Equivalent: Vitis vinifera (Dry)	3.6 g
<b>zinc gluconate</b>	<b>86 mg</b>
Equivalent: zinc	12 mg

**Other Ingredients (Excipients)**

**calcium hydrogen phosphate dihydrate**  
**hypromellose**  
**magnesium stearate**  
**microcrystalline cellulose**  
**sodium starch glycollate**

Public Summary



**Australian Government**

**Department of Health**  
Therapeutic Goods Administration

---

written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary